Through clinical transformation, in the future, a variety of strategies such as small molecule inhibitors, monoclonal antibodies, gene editing technology or RNA interference may be used to target RUNX1 in the aortic PVAT for the prevention of aortic dissection. The gene discussed is RUNX1; the disease is Aortic dissection.